MDWD241220P12500
- 0.10
- 0.000.00%
MediWound Newsroom
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Mediwound's Promising Outlook: Expansion and Trials Support Buy Rating
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28
MediWound Analyst Ratings
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Announces Target Price $30
Mediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market Potential
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
MediWound Analyst Ratings
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28
Buy Rating Justified by MediWound's Strong Financials and Product Expansion Potential
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Buy Rating Affirmed for Mediwound Amid Market Expansion and Positive Growth Prospects
Oppenheimer Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36
Mediwound (MDWD) Receives a Buy From Oppenheimer
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
MediWound Analyst Ratings
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Buy Rating Affirmed for Mediwound: Strategic Alliances and Financial Infusions Signal Strong Market Position for EscharEx
Buy Rating for Mediwound Backed by Strong Revenue Growth and Solid Pipeline Prospects